{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:14:21Z","timestamp":1766405661698,"version":"3.48.0"},"reference-count":30,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease that requires regular monitoring. The University of Alberta IBD Unit piloted a proactive outreach protocol for biologic-na\u00efve UC patients, including clinical and biochemical variables, and assessed its impact on UC care. Methods: Biologic-na\u00efve UC patients without follow-up for \u22656 months were recruited by phone and completed Partial Mayo, modified Sutherland Index, and MARS-5 questionnaires, as well as blood work and fecal calprotectin (FCP). Results were sent to each patient\u2019s gastroenterologist, who then completed a survey about intended UC management changes. Results: 81 patients completed the protocol. UC management was changed in 45 (55.6%) cases, with 82.2% of changes being expedited follow-up or management escalation. Six patients had active flares, and 17 with asymptomatic inflammation were identified. 23 patients underwent endoscopy, with 10 (43.4%) showing active disease. Six patients started biologic therapies based on protocol and endoscopic findings. UC management escalations were significantly predicted by FCP and Sutherland Index scores on logistic regression analysis. 86.4% of gastroenterologists rated the protocol helpful. Conclusions: Patient care can be improved by a one-time, proactive outreach program for biologic-na\u00efve UC. Outreach and monitoring in biologic-na\u00efve UC should include assessment of both FCP and clinical markers to improve UC management.<\/jats:p>","DOI":"10.3390\/diseases14010002","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:43:31Z","timestamp":1766403811000},"page":"2","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Proactive Fecal Calprotectin Collection in an Outreach Protocol for Biologic-Na\u00efve Ulcerative Colitis Patients\u2013Ulcerative Colitis Clinical Outreach (UCCO)"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8069-7060","authenticated-orcid":false,"given":"Scott","family":"MacKay","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-9574","authenticated-orcid":false,"given":"Denise","family":"Parsons","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candace","family":"Hagerman","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-9010","authenticated-orcid":false,"given":"Ellina","family":"Lytvyak","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levinus","family":"Dieleman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5314-4452","authenticated-orcid":false,"given":"Frank","family":"Hoentjen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3886-4213","authenticated-orcid":false,"given":"Karen","family":"Kroeker","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-3192","authenticated-orcid":false,"given":"Farhad","family":"Peerani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5588-2229","authenticated-orcid":false,"given":"Karen","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Gozdzik","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-9304","authenticated-orcid":false,"given":"Kunihiko","family":"Oguro","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"},{"name":"Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"McMullen","sequence":"additional","affiliation":[{"name":"Division of General Surgery, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0467-1840","authenticated-orcid":false,"given":"Brendan","family":"Halloran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/jcag\/gwad003","article-title":"The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary","volume":"6","author":"Windsor","year":"2023","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Solitano, V., D\u2019Amico, F., Fiorino, G., Paridaens, K., Peyrin-Biroulet, L., and Danese, S. (2020). Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092905"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e000853","DOI":"10.1136\/bmjgast-2021-000853","article-title":"Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis","volume":"9","author":"Louis","year":"2022","journal-title":"BMJ Open Gastro."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"Am. J. Med."},{"key":"ref_7","first-page":"1858","article-title":"Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis","volume":"19","author":"Samuel","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/00365521.2021.2022193","article-title":"Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis","volume":"57","author":"Ge","year":"2022","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41395-018-0272-8","article-title":"A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD)","volume":"114","author":"Cross","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cgh.2020.04.038","article-title":"Cost-effectiveness of telemedicine-directed specialized vs standard care for patients with inflammatory bowel diseases in a randomized trial","volume":"18","author":"Boonen","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e15505","DOI":"10.2196\/15505","article-title":"Telemonitoring of Crohn\u2019s Disease and Ulcerative Colitis (TECCU): Cost-effectiveness analysis","volume":"21","author":"Nos","year":"2019","journal-title":"J. Med. Internet Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/ibd\/izz252","article-title":"A noninferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc in the care of inflammatory bowel disease patients","volume":"26","author":"McCombie","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3748\/wjg.v29.i7.1139","article-title":"Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers","volume":"29","author":"Aguas","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/apt.17261","article-title":"Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild\u2013moderate ulcerative colitis","volume":"57","author":"Cortesi","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/bcp.14193","article-title":"The Medication Adherence Report Scale: A measurement tool for eliciting patients\u2019 reports of nonadherence","volume":"86","author":"Chan","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1572-0241.2007.01212.x","article-title":"Predictors of medication adherence in inflammatory bowel disease","volume":"102","author":"Ediger","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ibd.20933","article-title":"Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse","volume":"15","author":"Gisbert","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ecco-jcc\/jjz107","article-title":"Faecal calprotectin predicts endoscopic and histological activity in clinically quiescent ulcerative colitis","volume":"14","author":"Hart","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2136501","DOI":"10.1155\/2019\/2136501","article-title":"Systematic review with meta-analysis: Fecal calprotectin as a surrogate marker for predicting relapse in adults with ulcerative colitis","volume":"2019","author":"Li","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/MIB.0000000000001157","article-title":"Fecal calprotectin levels predict histological healing in ulcerative colitis","volume":"23","author":"Patel","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e24058","DOI":"10.1097\/MD.0000000000024058","article-title":"Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis","volume":"100","author":"Madi","year":"2021","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ashorov, O., Hamouda, D., Dickman, R., and Perets, T.T. (2020). Clinical accuracy of a new rapid assay for fecal calprotectin measurement. Clin. Lab., 66.","DOI":"10.7754\/Clin.Lab.2020.200126"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2036.2009.04164.x","article-title":"A new rapid home test for faecal calprotectin in ulcerative colitis","volume":"31","author":"Elkjaer","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.dld.2017.05.009","article-title":"Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients","volume":"49","author":"Bello","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Haisma, S.M., Galaurchi, A., Almahwzi, S., Adekanmi Balogun, J.A., Muller Kobold, A.C., and van Rheenen, P.F. (2019). Head-to-head comparison of three stool calprotectin tests for home use. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214751"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.cgh.2017.06.007","article-title":"Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity","volume":"15","author":"Heida","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/2\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:11:51Z","timestamp":1766405511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diseases14010002"],"URL":"https:\/\/doi.org\/10.3390\/diseases14010002","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}